

Curriculum Vitae

Peter S Hall

Contact details at: <https://www.ed.ac.uk/profile/peter-hall>

Professional Qualifications

2012	PhD	<i>Academic Unit of Health Economics, University of Leeds</i>
2006	MRCP (UK)	<i>Royal College of Physicians of Edinburgh</i>
2003	MB ChB	<i>Faculty of Medicine, University of Edinburgh</i>

Current Positions

READER IN CANCER INFORMATICS	Edinburgh Cancer Research Centre, University of Edinburgh
HONORARY CONSULTANT MEDICAL ONCOLOGIST	Edinburgh Cancer Centre, NHS Lothian
VISITING ASSOCIATE PROFESSOR OF HEALTH ECONOMICS	Academic Unit of Health Economics, University of Leeds
HEALTH ECONOMICS GROUP LEAD	University of Edinburgh Clinical Trials Unit

Recent Previous Appointments

Aug 12 – Mar 17	ASSOCIATE CLINICAL DIRECTOR	NIHR Diagnostic Evidence Cooperative, Leeds.
Aug 12 – Mar 15	CLINICAL LECTURER	Academic Unit of Health Economics, University of Leeds
Aug 08 - Aug 12	CLINICAL RESEARCH FELLOW	Clinical Trials Research Unit, University of Leeds

Research Themes

- Health Technology Assessment for new cancer interventions
- Bayesian decision analysis for efficient research design
- Economic evaluation of biomarkers and personalised medicine strategies
- Methods for the measurement of clinical and economic outcomes using Real World Data

Current Committee and Management Positions

- Clinical lead for South East Scotland Cancer Research Network Breast trials portfolio.
- Editorial Board, Pharmacoeconomics journal (2013 – present)
- National Cancer Research Institute (NCRI) Psychosocial Oncology and Survivorship Clinical Studies Group Service Development, Delivery and Evaluation subgroup (2012-present)
- Data Monitoring and Ethics Committee for NIHR UK STAR trial
- Trial Steering Committee for international LOTUS trial
- NHS Lothian Formulary Committee (2016 - present)
- NICE Technology Appraisal Committee Member Feb 2017 - present

Current Research Funding

2019-20 Scottish Funding Council £30,000 (Chief Investigator) Implementing a regional electronic platform for PROMs and PREMs in cancer care in South East Scotland. [Data science]

2018-20 Breast Cancer Institute £125,724 (Chief Investigator) Supporting shared decision making in early and advanced breast cancer: What matters to patients in an era of personalised care. [Discrete choice experiment]

2018-21 CSO £249,100 (Humphries et al, Co-app) Pilot Trial of the Mini-AFTERc intervention to manage Fears of Cancer Recurrence in patients with breast cancer [Feasibility RCT]

2018 – 2020 MacMillan Cancer Support £105,664. (Co-app, Bagnall et al.) Systematic review of effectiveness and cost-effectiveness of digital supportive interventions for people with cancer that cannot be cured.

2018 – 2019 ABPI Research Collaboration £140,000 (Pfizer, Novartis, Amgen, AstraZeneca) (Hall et al.) Data intelligence for the value appraisal of personalised healthcare technologies for cancer within the South East Scotland Cancer Network (LCDI)

2017-2020 Marie Curie and Scottish CSO £85,000 (Co-app, Fallon, Laird et al.) ENErGy: Exercise and Nutritional Rehabilitation in patients with advanced cancer. [Phase II RCT]

2017 – 2020 EME 15/48/20 £897,394 (Co-app) CardiacCARE: Cardiac protection during adjuvant chemotherapy for early breast cancer, initiated by Troponin I. [Phase II RCT]

2017 – 2020 CRUK (Co-app) c-TRAK-TN: ctDNA to Detect Cancer Cells After Standard Treatment to Trigger Immunotherapy in Early Stage Triple Negative Breast Cancer Patients [Phase II RCT]

2017 – 2020 NIHR HTA 15/130/95 £1,024,453 (Co-app, Patterson, Norrie et al.) The ALLEGRO trial: A placebo controlled randomised trial of intravenous Lidocaine in accelerating Gastrointestinal Recovery after colorectal surgery

2017 – 2019 Health Foundation £400,000 (co-app), Marti et al. Allocative efficiency in end of life care.

2017 – 2023 CRUK Programme Grant £3,437,297 (co-app, Morris et al.) Creating a UK Colorectal Cancer Intelligence Hub

2016-2024 NIHR (Health Technology Assessment), £3.3 million (co-applicant, lead for economic modelling) (Stein R, et al.) “Optimal personalised treatment of breast cancer using multi-parameter analysis (OPTIMA)”.

2013–2022 NIHR (Health Technology Assessment), £2 million (co-app, lead for economic modelling) (Dunn, Evans, et al.) “Mammographic surveillance in breast cancer patients aged over 50 years” Mammo-50: A multi-centre, randomised, controlled, phase III trial of annual versus less frequent mammography.

Recently completed PhD Students

2016-2019 Katie Spencer, University of Leeds, MRC Clinical Research Fellowship, “Cost-effectiveness of the palliative radiotherapy treatments delivered within the English NHS”

Selected Recent Publications

- 2019 Earl, H.M., Hiller, L., Vallier, ...Hall PS, Dunn J et al. *6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial*. **The Lancet**. 2019 393(1019):2599-2612
- Spencer, K., Velikova, G., Henry, A., Westhoff, P., Hall, P. and van der Linden, Y.M. *Net Pain Relief After Palliative Radiation Therapy for Painful Bone Metastases: A Useful Measure to Reflect Response Duration? A Further Analysis of the Dutch Bone Metastasis Study*. **International Journal of Radiation Oncology** 2019 105(3):559-566.
- Abel, L., Shinkins, B., Smith, A., Sutton, A.J., Sagoo, G.S., Uchegbu, I., Allen, A.J., Graziadio, S., Moloney, E., Yang, Y. and Hall, P. *Early economic evaluation of diagnostic technologies: experiences of the NIHR Diagnostic Evidence Co-operatives*. **Medical Decision Making**, (online ahead of print)
- Gray, E., Marti, J., Brewster, D.H., Wyatt, J.C., Piaget-Rossel, R. and Hall, P.S. *Real-world evidence was feasible for estimating effectiveness of chemotherapy in breast cancer: a cohort study*. **Journal of clinical epidemiology**, 2019 109:125-132
- 2018 Gray E, Donten A, Payne K, Hall PS. *Survival estimates stratified by the Nottingham Prognostic Index for early breast cancer: a systematic review and meta-analysis of observational studies*. **Systematic reviews**. 2018 7(1):142.
- Gray E, Marti J, Brewster DH, Wyatt JC, Hall PS. *Independent validation of the PREDICT breast cancer prognosis prediction tool in 45,789 patients using Scottish Cancer Registry data*. **British journal of cancer**. 2018 119(7):808.
- Hall PS, Mitchell ED, Smith AF, Cairns DA, Messenger M, Hutchinson M, Wright J, Vinall-Collier K, Corps C, Hamilton P, Meads D. *The future for diagnostic tests of acute kidney injury in critical care: evidence synthesis, care pathway analysis and research prioritisation*. **Health Technology Assessment**. 2018 4;22(32).
- 2017 PS Hall, A Smith, C Hulme, et al. *Value of Information Analysis of Multi-parameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial*. **Value in Health** 2017
- PS Hall. *Real-world data for efficient health technology assessment*. **European Journal of Cancer** 2017 79: 235-237
- PS Hall, S Lord, M Collinson, et al. *A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)*. **British Journal of Cancer** 2017 116(4):472-478
- 2016 John M. S. Bartlett; Jane Bayani; Andrea Marshall .. Hall PS et al. *Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others* **JNCI** 2016 108(9): djw050
- Mehanna H, Wong W... Hall PS et al. *PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer*. **NEJM** 2016 374:1444-1454